Gmünder H, Kuratli K, Keck W
Pharma Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Antimicrob Agents Chemother. 1995 Jan;39(1):163-9. doi: 10.1128/AAC.39.1.163.
The quinolones inhibit the A subunit of DNA gyrase in the presence of Mg2+ by interrupting the DNA breakage and resealing steps, and the latter step is also retarded without quinolones if Mg2+ is replaced by Ca2+. Pyrimido[1,6-a]benzimidazoles have been found to represent a new class of potent DNA gyrase inhibitors which also act at the A subunit. To determine alterations in the DNA sequence specificity of DNA gyrase for cleavage sites in the presence of inhibitors of both classes or in the presence of Ca2+, we used DNA restriction fragments of 164, 85, and 71 bp from the pBR322 plasmid as model substrates. Each contained, at a different position, the 20-bp pBR322 sequence around position 990, where DNA gyrase preferentially cleaves in the presence of quinolones. Our results show that pyrimido[1,6-a]benzimidazoles have a mode of action similar to that of quinolones; they inhibit the resealing step and influence the DNA sequence specificity of DNA gyrase in the same way. Differences between inhibitors of both classes could be observed only in the preferences of DNA gyrase for these cleavage sites. The 20-bp sequence appeared to have some properties that induced DNA gyrase to cleave all three DNA fragments in the presence of inhibitors within this sequence, whereas cleavage in the presence of Ca2+ was in addition dependent on the length of the DNA fragments.
喹诺酮类药物在Mg2+存在的情况下,通过中断DNA断裂和重新封闭步骤来抑制DNA回旋酶的A亚基;如果用Ca2+取代Mg2+,即使没有喹诺酮类药物,后一步骤也会受到阻碍。已发现嘧啶并[1,6-a]苯并咪唑代表一类新的强效DNA回旋酶抑制剂,其作用靶点也是A亚基。为了确定在两类抑制剂存在的情况下或在Ca2+存在的情况下,DNA回旋酶对切割位点的DNA序列特异性的改变,我们使用了来自pBR322质粒的164、85和71 bp的DNA限制性片段作为模型底物。每个片段在不同位置包含pBR322质粒990位点附近的20 bp序列,在喹诺酮类药物存在的情况下,DNA回旋酶优先在此处切割。我们的结果表明,嘧啶并[1,6-a]苯并咪唑的作用方式与喹诺酮类药物相似;它们抑制重新封闭步骤,并以相同方式影响DNA回旋酶的DNA序列特异性。仅在DNA回旋酶对这些切割位点的偏好方面可以观察到两类抑制剂之间的差异。20 bp序列似乎具有一些特性,能诱导DNA回旋酶在该序列存在抑制剂的情况下切割所有三个DNA片段,而在Ca2+存在的情况下切割还取决于DNA片段的长度。